Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China.
Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China; Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Maternal and Child Health Care Hospital of Shandong Province affiliated to Qingdao University, Shandong Province, China.
Biomed Pharmacother. 2023 Jul;163:114786. doi: 10.1016/j.biopha.2023.114786. Epub 2023 Apr 27.
Colorectal cancer (CRC) is one of the most common digestive diseases worldwide. It has steadily ascended to the top three cancers in terms of incidence and mortality. The primary cause is the inability to diagnose it at an early stage. Therefore, early detection and diagnosis are essential for colorectal cancer prevention. Although there are now various methods for CRC early detection, in addition to recent developments in surgical and multimodal therapy, the poor prognosis and late detection of CRC still remain significant. Thus, it is important to investigate novel technologies and biomarkers to improve the sensitization and specification of CRC diagnosis. Here, we present some common methods and biomarkers for early detection and diagnosis of CRC, we hope this review will encourage the adoption of screening programs and the clinical use of these potential molecules as biomarkers for CRC early detection and prognosis.
结直肠癌(CRC)是全球最常见的消化系统疾病之一。它的发病率和死亡率稳步上升,已位居癌症发病率和死亡率的前三位。主要原因是早期诊断能力不足。因此,早期发现和诊断对于结直肠癌的预防至关重要。尽管现在有多种 CRC 早期检测方法,除了手术和多模式治疗的最新进展外,CRC 的预后不良和晚期发现仍然是一个重大问题。因此,探索新技术和生物标志物以提高 CRC 诊断的敏感性和特异性非常重要。在这里,我们介绍了一些用于 CRC 早期检测和诊断的常见方法和生物标志物,希望这篇综述将鼓励采用筛查计划,并将这些潜在分子作为 CRC 早期检测和预后的生物标志物进行临床应用。